Dimension

Dimension is a multistage, research-oriented investment firm singularly focused at the intersection of technology and life sciences. The firm's core conviction is that "technology and biology are converging to create the next generation of transformative companies"—the digitization of life sciences, driven by exponential growth in biological data and advances in AI/ML, is enabling a new class of platform companies that will dominate the industry. Dimension invests across the full continuum of the tech-bio ecosystem: drug discovery platforms powered by AI/ML, lab automation and instrumentation, software and data infrastructure for biopharma, and clinical-stage therapeutics enabled by computational advances. The firm backs only companies where computational biologists, ML engineers, and AI practitioners are deeply intermingled with chemists and biologists—requiring that 25–40% of the founding team be computational scientists. With Fund I ($350M) and Fund II ($500M), Dimension targets roughly 20 portfolio companies per fund, writing checks from $1M to $30M+ across all stages from incubation through public markets.